Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
* Trial met all primary and key secondary endpoints, including progression-free survival and overall survival
* Company intends to include these data
